Small
study shows antibody growth from AstraZeneca, Sputnik
Light COVID-19 vaccine mix
Send a link to a friend
[September 27, 2021]
MOSCOW (Reuters) - A small-scale clinical
study of the combined use of the AstraZeneca and Sputnik Light vaccines
against COVID-19 has shown strong antibody growth in a majority of the
study's participants, the Russian Direct Investment Fund said on Monday.
|
The data was collected from 20 people who took part in a 100-person
study in Azerbaijan that began in February. They first received the
AstraZeneca shot followed by the one-dose Russian-made Sputnik Light
shot 29 days later, RDIF said.
"According to the results of the interim analysis, a fourfold or
higher increase in neutralising antibodies to the spike protein
(S-protein) of the SARS-CoV-2 was found in 85% of the volunteers on
the 57th day of the study," RDIF said.
[to top of second column] |
(Reporting by Maxim Rodionov; Writing by Alexander Marrow; Editing
by Louise Heavens)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |